Telmisartan to prevent recurrent stroke and cardiovascular events
| العنوان: | Telmisartan to prevent recurrent stroke and cardiovascular events |
|---|---|
| المؤلفون: | Yusuf, S, Diener, Hc, Sacco, Rl, Cotton, D, Ounpuu, S, Lawton, Wa, Palesch, Y, Martin, Rh, Albers, Gw, Bath, P, Bornstein, N, Chan, Bp, Chen, St, Cunha, L, Dahlöf, B, DE KEYSER, J, Donnan, Ga, Estol, C, Gorelick, P, Gu, V, Hermansson, K, Hilbrich, L, Kaste, M, Lu, C, Machnig, T, Pais, P, Roberts, R, Skvortsova, V, Teal, P, Toni, Danilo, Vandermaelen, C, Voigt, T, Weber, M, Yoon, Bw, Lembo, Giuseppe, Rasura, Maurizia, Sacchetti, Maria Luisa |
| المساهمون: | Hamilton General Hospital, Population Health Research Institute, McMaster University [Hamilton, Ontario]-Hamilton General Hospital, Universität Duisburg-Essen [Essen], Miller School of Medicine, University of Miami [Coral Gables], Institute of Medicine, Sahlgrenska University Hospital, Helsinki University, Institut de Génétique Moléculaire de Montpellier ( IGMM ), Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ), Neuroépidémiologie Tropicale et Comparée ( NETEC ), Génomique, Environnement, Immunité, Santé, Thérapeutique ( GEIST FR CNRS 3503 ) -Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Université de Limoges ( UNILIM ), Service de Neurologie [CHU Limoges], CHU Limoges, University of Miami Leonard M. Miller School of Medicine (UMMSM), Sahlgrenska University Hospital [Gothenburg], University of Helsinki, Institut de Génétique Moléculaire de Montpellier (IGMM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Yusuf, S, Diener, Hc, Sacco, Rl, Cotton, D, Ounpuu, S, Lawton, Wa, Palesch, Y, Martin, Rh, Albers, Gw, Bath, P, Bornstein, N, Chan, Bp, Chen, St, Cunha, L, Dahlof, B, De Keyser, J, Donnan, Ga, Estol, C, Gorelick, P, Gu, V, Hermansson, K, Hilbrich, L, Kaste, M, Lu, C, Machnig, T, Pais, P, Roberts, R, Skvortsova, V, Teal, P, Toni, D, Vandermaelen, C, Voigt, T, Weber, M, Yoon, Bw, Comi, Giancarlo, PRoFESS Stuy, Group, Gerontology, Faculteit Medische Wetenschappen/UMCG |
| المصدر: | New England Journal of Medicine New England Journal of Medicine, Massachusetts Medical Society, 2008, 359 (12), pp.1225-37. 〈10.1056/NEJMoa0804593〉 New England Journal of Medicine, Massachusetts Medical Society, 2008, 359 (12), pp.1225-37. ⟨10.1056/NEJMoa0804593⟩ New England Journal of Medicine, 359(12), 1225-1237. MASSACHUSETTS MEDICAL SOC |
| بيانات النشر: | HAL CCSD, 2008. |
| سنة النشر: | 2008 |
| مصطلحات موضوعية: | Male, MESH: Treatment Failure, MESH : Recurrence, Myocardial Infarction, MESH : Aged, Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, BLOOD-PRESSURE, 0302 clinical medicine, DESIGN, Secondary Prevention, MESH : Cardiovascular Diseases, Myocardial infarction, MESH: Middle Aged, Hazard ratio, General Medicine, MESH: Follow-Up Studies, MESH: Blood Pressure, 3. Good health, MESH: Myocardial Infarction, MESH : Diabetes Mellitus, Cardiovascular Diseases, Creatinine, MESH : Angiotensin-Converting Enzyme Inhibitors, Ramipril, medicine.medical_specialty, MESH: Diabetes Mellitus, MESH: Creatinine, [ SDV.MHEP.GEG ] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology, Article, MESH: Stroke, 03 medical and health sciences, MESH : Treatment Failure, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Diabetes Mellitus, Humans, MESH : Middle Aged, COMBINATION, MESH: Kaplan-Meier Estimate, Aged, Heart Failure, MESH: Humans, VASCULAR EVENTS, MORTALITY, MESH : Humans, MESH : Creatinine, MESH: Cardiovascular Diseases, MESH : Follow-Up Studies, medicine.disease, MESH: Benzoates, RAMIPRIL, Blood pressure, MESH : Potassium, Potassium, Benzimidazoles, MESH : Heart Failure, MESH: Female, 030217 neurology & neurosurgery, MESH : Stroke, RATIONALE, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, Benzoates, RANDOMIZED TRIAL, DOUBLE-BLIND, MESH : Female, sartani, ictus, trial clinico, Telmisartan, Treatment Failure, Stroke, MESH: Aged, [SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology, MESH: Angiotensin-Converting Enzyme Inhibitors, Middle Aged, [ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, MESH : Benzimidazoles, Cardiology, Female, medicine.drug, MESH : Benzoates, MESH : Male, MESH : Kaplan-Meier Estimate, Internal medicine, Diabetes mellitus, medicine, MESH : Blood Pressure, HIGH-RISK PATIENTS, business.industry, Angiotensin II, MESH: Male, Surgery, MESH: Recurrence, MESH: Heart Failure, MESH: Potassium, MESH : Myocardial Infarction, business, MESH: Benzimidazoles, Follow-Up Studies |
| الوصف: | Background: Prolonged lowering of blood pressure after a stroke reduces the risk of recurrent stroke. In addition, inhibition of the renin-angiotensin system in high-risk patients reduces the rate of subsequent cardiovascular events, including stroke. However, the effect of lowering of blood pressure with a renin-angiotensin system inhibitor soon after a stroke has not been clearly established. We evaluated the effects of therapy with an angiotensin-receptor blocker, telmisartan, initiated early after a stroke.Methods: In a multicenter trial involving 20,332 patients who recently had an ischemic stroke, we randomly assigned 10,146 to receive telmisartan (80 mg daily) and 10,186 to receive placebo. The primary outcome was recurrent stroke. Secondary outcomes were major cardiovascular events (death from cardiovascular causes, recurrent stroke, myocardial infarction, or new or worsening heart failure) and new-onset diabetes.Results: The median interval from stroke to randomization was 15 days. During a mean follow-up of 2.5 years, the mean blood pressure was 3.8/2.0 mm Hg lower in the telmisartan group than in the placebo group. A total of 880 patients (8.7%) in the telmisartan group and 934 patients (9.2%) in the placebo group had a subsequent stroke (hazard ratio in the telmisartan group, 0.95; 95% confidence interval [CI], 0.86 to 1.04; P=0.23). Major cardiovascular events occurred in 1367 patients (13.5%) in the telmisartan group and 1463 patients (14.4%) in the placebo group (hazard ratio, 0.94; 95% CI, 0.87 to 1.01; P=0.11). New-onset diabetes occurred in 1.7% of the telmisartan group and 2.1% of the placebo group (hazard ratio, 0.82; 95% CI, 0.65 to 1.04; P=0.10).Conclusions: Therapy with telmisartan initiated soon after an ischemic stroke and continued for 2.5 years did not significantly lower the rate of recurrent stroke, major cardiovascular events, or diabetes. (ClinicalTrials.gov number, NCT00153062.). |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 0028-4793 1533-4406 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c9ada1720b25d6ae649058a332967a5Test https://hal-unilim.archives-ouvertes.fr/hal-00626465Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....5c9ada1720b25d6ae649058a332967a5 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 00284793 15334406 |
|---|